中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2010年
11期
1163-1164
,共2页
雷贝拉唑%雷尼替丁枸橼酸铋%螺杆菌,幽门%十二指肠溃疡
雷貝拉唑%雷尼替丁枸櫞痠鉍%螺桿菌,幽門%十二指腸潰瘍
뢰패랍서%뢰니체정구연산필%라간균,유문%십이지장궤양
Rabeprazole%Ranitidine bismuth citrate%Helicobacter pylori%Duodenal ulcer
目的 观察含雷贝拉唑的四联4日疗法根除幽门螺杆菌(Hp)的效果及其治疗Hp阳性十二指肠球部溃疡的疗效.方法 选择120例Hp阳性十二指肠球部溃疡患者,将其随机分为治疗组和对照组,各60例.治疗组口服雷贝拉唑10 mg/次,雷尼替丁枸橼酸铋(RBC)350 mg/次,阿莫西林1 000 mg/次,呋喃唑酮100 mg/次,均2次/d,共4 d.对照组口服奥美拉唑20 mg/次,阿莫西林1 000 mg/次,克拉霉素500 mg/次,均2次/d,共7 d.抗Hp治疗后继续服用雷贝拉唑10 mg/次或奥美拉唑20 mg/次,1次/d,疗程2周.观察治疗后4～6周时的Hp根除率、溃疡愈合率及随访半年、1年时的溃疡复发率和Hp再感染率.结果 治疗后4～6周,治疗组和对照组溃疡愈合率分别为98.2%和93.1%,差异无统计学意义(P＞0.05);Hp根除率分别为96.4%和77.6%,差异有统计学意义(P＜0.01).治疗组和对照组随访半年溃疡复发率分别为3.8%和15.7%,随访1年分别为5.9%和20.0%,差异均有统计学意义(P＜0.05);随访半年Hp再感染率分别为7.5%和21.6%,随访1年分别为11.8%和28.0%,差异均有统计学意义(P＜0.05).结论 含雷贝拉唑和RBC的四联4日疗法是一种短程、高效、安全的根除Hp和促进溃疡愈合的方法.
目的 觀察含雷貝拉唑的四聯4日療法根除幽門螺桿菌(Hp)的效果及其治療Hp暘性十二指腸毬部潰瘍的療效.方法 選擇120例Hp暘性十二指腸毬部潰瘍患者,將其隨機分為治療組和對照組,各60例.治療組口服雷貝拉唑10 mg/次,雷尼替丁枸櫞痠鉍(RBC)350 mg/次,阿莫西林1 000 mg/次,呋喃唑酮100 mg/次,均2次/d,共4 d.對照組口服奧美拉唑20 mg/次,阿莫西林1 000 mg/次,剋拉黴素500 mg/次,均2次/d,共7 d.抗Hp治療後繼續服用雷貝拉唑10 mg/次或奧美拉唑20 mg/次,1次/d,療程2週.觀察治療後4～6週時的Hp根除率、潰瘍愈閤率及隨訪半年、1年時的潰瘍複髮率和Hp再感染率.結果 治療後4～6週,治療組和對照組潰瘍愈閤率分彆為98.2%和93.1%,差異無統計學意義(P＞0.05);Hp根除率分彆為96.4%和77.6%,差異有統計學意義(P＜0.01).治療組和對照組隨訪半年潰瘍複髮率分彆為3.8%和15.7%,隨訪1年分彆為5.9%和20.0%,差異均有統計學意義(P＜0.05);隨訪半年Hp再感染率分彆為7.5%和21.6%,隨訪1年分彆為11.8%和28.0%,差異均有統計學意義(P＜0.05).結論 含雷貝拉唑和RBC的四聯4日療法是一種短程、高效、安全的根除Hp和促進潰瘍愈閤的方法.
목적 관찰함뢰패랍서적사련4일요법근제유문라간균(Hp)적효과급기치료Hp양성십이지장구부궤양적료효.방법 선택120례Hp양성십이지장구부궤양환자,장기수궤분위치료조화대조조,각60례.치료조구복뢰패랍서10 mg/차,뢰니체정구연산필(RBC)350 mg/차,아막서림1 000 mg/차,부남서동100 mg/차,균2차/d,공4 d.대조조구복오미랍서20 mg/차,아막서림1 000 mg/차,극랍매소500 mg/차,균2차/d,공7 d.항Hp치료후계속복용뢰패랍서10 mg/차혹오미랍서20 mg/차,1차/d,료정2주.관찰치료후4～6주시적Hp근제솔、궤양유합솔급수방반년、1년시적궤양복발솔화Hp재감염솔.결과 치료후4～6주,치료조화대조조궤양유합솔분별위98.2%화93.1%,차이무통계학의의(P＞0.05);Hp근제솔분별위96.4%화77.6%,차이유통계학의의(P＜0.01).치료조화대조조수방반년궤양복발솔분별위3.8%화15.7%,수방1년분별위5.9%화20.0%,차이균유통계학의의(P＜0.05);수방반년Hp재감염솔분별위7.5%화21.6%,수방1년분별위11.8%화28.0%,차이균유통계학의의(P＜0.05).결론 함뢰패랍서화RBC적사련4일요법시일충단정、고효、안전적근제Hp화촉진궤양유합적방법.
Objective To observe the effects of the quadruple chemotherapy including rabeprazole on Helicobacter pylori (Hp) and on Hp-positive duodenal bulbar ulcer.Methods One hundred and twenty patients with Hp-positive duodenal bulbar ulcer were randomized into groups therapy and control,60 in each.Therapy group received oral rabeprazole (10 mg/times),ranitidine bismuth citrate (RBC,350 mg/times),amoxicillin (1 000 mg/times),furazolidone (100 mg/times),twice/d,4 d altogether.Control group received oral omeprazole (20 mg/times),amoxicillin (1 000 mg/times),clarithromycin (500 mg/times),twice/d,7 d altogether.After anti-Hp treatment,rabeprazole (10 mg/times) or omeprazol (20 mg/times) was continuously used,once/d,2 weeks.The Hp eradication rate and ulcer healing rate 4～6 weeks after treatment,and ulcer relapse rate and Hp reinfection after six-month or 1-year follow up were observed.Results The ulcer healing rates of groups therapy and control were 98.2%,93.1%,respectively,4～6 weeks after treatment,the difference was not significant (P＞0.05),and the Hp eradication rates were 96.4%,77.6%,respectively,the difference was significant (P＜0.01).The ulcer relapse rates were 3.8%,15.7%,respectively,after 6-month follow up,and 5.9%,20.0%,respectively,after 12-month follow up,the difference was significant (P＜0.05).Hp re-infection rates were 7.5%,21.6%,respectively,after 6-month follow up,and 11.8%,28.0%,respectively,after 12-month follow up,the difference was significant (P＜0.05).Conclusion The 4-day quadruple chemotherapy of combined rabeprazole and RBC is a short-range,efficient and safe method in Hp eradication and ulcer healing promotion.
